Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases

Ageing Research Reviews(2022)10.1016/j.arr.2022.101819Source: DataRank Database

Determinants of approved acetylcholinesterase inhibitor response outcomes in Alzheimer’s disease: relevance for precision medicine in neurodegenerative diseases is a research paper published in Ageing Research Reviews (2022). On theSindex it has a DataRank of 0. It has been cited 42 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access42 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 6.01)OA: bronzeTopics (53)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Andrea Vergallo ORCID,Stefan Teipel ORCID,Pablo Lemercier ORCID,Filippo Sean Giorgi ORCID,Audrey Gabelle ORCID

Live enrichment

PubMed:36526257 OpenAlex:https://openalex.org/W4313421180

National Institute on Aging

Grant: R01AG055865

National Institute on Aging

Grant: R01AG056478

National Institute on Aging

Grant: R01AG075998

National Institutes of Health

Grant: 3R01AG056478-04S1

Retinal Imaging of Alzheimer's Disease Pathology

National Institutes of Health

Grant: 5R01AG055865-08

Alzheimer's Disease Hallmark Pathology and Associated Inflammation in the Retina

National Institutes of Health

Grant: 5R01AG075998-03

The role of Chlamydia pneumoniae infection in Alzheimer's Disease

European Commission

Grant: 101058516

eBRAIN-Health - Actionable Multilevel Health Data

FWCI

6.01

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

bronzeLicense: Elsevier TDM

journalhttps://www.sciencedirect.com/science/article/am/pii/S1568163722002616?via%3Dihub

publisherhttps://www.sciencedirect.com/science/article/am/pii/S1568163722002616?via%3Dihub

publisherhttps://api.elsevier.com/content/article/PII:S1568163722002616?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1568163722002616?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.arr.2022.101819

Fields of Study

Cholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsNeurological Disorders and Treatments03 medical and health sciences0302 clinical medicineHumansCholinesterase InhibitorsAlzheimer DiseaseAcetylcholinesteraseNeurodegenerative DiseasesPrecision Medicine

MeSH Terms

AcetylcholinesteraseAlzheimer DiseaseCholinesterase InhibitorsHumansNeurodegenerative DiseasesPrecision Medicine

Keywords

AcetylcholinesteraseDiseaseMedicineAlzheimer's diseaseRelevance (law)Precision medicineDegenerative diseaseNeurosciencePharmacologyInternal medicinePsychologyPathologyBiologyEnzymeBiochemistrySettore BIO/14 - FARMACOLOGIAAlzheimer Disease: diagnosis610Alzheimer Disease: drug therapyAlzheimer Disease: geneticsDisease-modifyingBasal forebrainAcetylcholinesterase: therapeutic useAlzheimer DiseaseHumansAmyloid-βinfo:eu-repo/classification/ddc/610Cholinesterase Inhibitors: therapeutic useCholinesterase Inhibitors: pharmacologyCholinergic systemNeurodegenerative DiseasesAcetylcholinesterase inhibitors; Alzheimer’s disease; Amyloid-β; Basal forebrain; Cholinergic system; Disease-modifyingAcetylcholinesterase inhibitorsNeurodegenerative Diseases: drug therapyCholinesterase InhibitorsAlzheimer’s disease

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being